April 01, 2022
Video
Nilanjan Ghosh, MD, PhD, discusses when a Bruton’s tyrosine kinase inhibitor would be preferred over a BCL-2 inhibitor as first-line therapy for patients with chronic lymphocytic leukemia.
November 18, 2020
Video
Nilanjan Ghosh, MD, discusses the effect coronavirus disease 2019 had on using chimeric antigen receptor T-cell therapy to treat patients with diffuse large B-cell lymphoma.
August 20, 2020
Video
Nilanjan Ghosh, MD, discusses the current unmet needs in mantle cell lymphoma and how Bruton’s tyrosine kinase inhibitors are being looked at to fill that need for patients with high-risk disease in the first line.
August 05, 2020
Video
Nilanjan Ghosh, MD, discusses the significance of the data from a pilot study of lisocabtagene maraleucel in patients ineligible for second-line transplant with relapsed/refractory aggressive large B-cell non-Hodgkin lymphoma.